Rani Therapeutics Holdings, Inc.
RANINASDAQHealthcare● Active
$0.84
+$0.01(+1.22%)
Market Cap$54842672
P/E Ratio—
52W High$3.87
52W Low$0.387
Rani Therapeutics Holdings, Inc. (RANI) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
RANI · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 15, 2026EPS Actual
-$0.04
Est. -$0.06 · +33.3%
Revenue
$0.00B
Est. $0.00B · +51.8%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 15, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 1-Quarter EPS Beat Streak
RANI reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 6, 2026 | -$0.05 | — | — | — | $0.00B | — |
| ▲ Q2 FY2026 | May 15, 2026 | -$0.06 | -$0.04 | +33.3% | $0.00B | $0.00B | +51.8% |
| ▼ Q1 FY2026 | Mar 26, 2026 | -$0.03 | -$0.07 | -133.3% | $0.00B | $0.01B | -70.8% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -$0.09 | -$0.12 | -33.3% | — | $0.01B | — |
| ▲ Q3 FY2025 | Aug 7, 2025 | -$0.19 | -$0.18 | +5.3% | — | — | — |
| — Q2 FY2025 | May 13, 2025 | -$0.22 | -$0.22 | +0.0% | $0.00B | — | — |
| ▼ Q1 FY2025 | Mar 31, 2025 | -$0.24 | -$0.27 | -12.5% | $0.00B | — | — |
| ▼ Q4 FY2024 | Nov 14, 2024 | -$0.22 | -$0.24 | -9.1% | — | — | — |
Q3 FY2026
Aug 6, 2026
EPS Actual
—
EPS Est.
-$0.05
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 15, 2026Beat
EPS Actual
-$0.04
EPS Est.
-$0.06
EPS Surpr.
+33.3%
Revenue
$0.00B
Q1 FY2026
Mar 26, 2026Miss
EPS Actual
-$0.07
EPS Est.
-$0.03
EPS Surpr.
-133.3%
Revenue
$0.00B
Q4 FY2025
Nov 6, 2025Miss
EPS Actual
-$0.12
EPS Est.
-$0.09
EPS Surpr.
-33.3%
Revenue
—
Q3 FY2025
Aug 7, 2025Beat
EPS Actual
-$0.18
EPS Est.
-$0.19
EPS Surpr.
+5.3%
Revenue
—
Q2 FY2025
May 13, 2025
EPS Actual
-$0.22
EPS Est.
-$0.22
EPS Surpr.
+0.0%
Revenue
$0.00B
Q1 FY2025
Mar 31, 2025Miss
EPS Actual
-$0.27
EPS Est.
-$0.24
EPS Surpr.
-12.5%
Revenue
$0.00B
Q4 FY2024
Nov 14, 2024Miss
EPS Actual
-$0.24
EPS Est.
-$0.22
EPS Surpr.
-9.1%
Revenue
—
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-0.05 | $-0.05 | $-0.05 | 1 |
| Q3 FY2027 | $-0.05 | $-0.05 | $-0.05 | 1 |
| Q2 FY2027 | $-0.04 | $-0.04 | $-0.04 | 1 |
| Q1 FY2027 | $-0.04 | $-0.04 | $-0.04 | 1 |
| Q4 FY2026 | $-0.05 | $-0.05 | $-0.05 | 1 |
| Q3 FY2026 | $-0.05 | $-0.05 | $-0.05 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 1 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 1 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 2 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 15, 2026 | +33.3% | $1.11 | $1.08 | -2.70% |
| ▼ Q1 FY2026 | Mar 26, 2026 | -133.3% | $1.14 | $1.08 | -5.26% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -33.3% | $2.50 | $2.27 | -9.20% |
| ▲ Q3 FY2025 | Aug 7, 2025 | +5.3% | $0.55 | $0.53 | -3.04% |
| ▲ Q2 FY2025 | May 13, 2025 | +0.0% | $0.61 | $0.48 | -21.42% |
| ▼ Q1 FY2025 | Mar 31, 2025 | -12.5% | $1.36 | $1.26 | -7.35% |
| ▼ Q4 FY2024 | Nov 14, 2024 | -9.1% | $2.47 | $2.35 | -4.86% |
| ▲ Q3 FY2024 | Aug 6, 2024 | +10.3% | $2.44 | $2.50 | +2.46% |
Q2 FY2026-2.70%
Report Date
May 15, 2026
EPS Beat/Miss
+33.3%
Price Before
$1.11
Price After
$1.08
Q1 FY2026-5.26%
Report Date
Mar 26, 2026
EPS Beat/Miss
-133.3%
Price Before
$1.14
Price After
$1.08
Q4 FY2025-9.20%
Report Date
Nov 6, 2025
EPS Beat/Miss
-33.3%
Price Before
$2.50
Price After
$2.27
Q3 FY2025-3.04%
Report Date
Aug 7, 2025
EPS Beat/Miss
+5.3%
Price Before
$0.55
Price After
$0.53
Q2 FY2025-21.42%
Report Date
May 13, 2025
EPS Beat/Miss
+0.0%
Price Before
$0.61
Price After
$0.48
Q1 FY2025-7.35%
Report Date
Mar 31, 2025
EPS Beat/Miss
-12.5%
Price Before
$1.36
Price After
$1.26
Q4 FY2024-4.86%
Report Date
Nov 14, 2024
EPS Beat/Miss
-9.1%
Price Before
$2.47
Price After
$2.35
Q3 FY2024+2.46%
Report Date
Aug 6, 2024
EPS Beat/Miss
+10.3%
Price Before
$2.44
Price After
$2.50
Avg Beat Reaction-6.18%
Avg Miss Reaction-6.67%
Beat Rate4 / 8 quarters
Largest Move-21.42% (Q2 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: RANI ends December
Rani Therapeutics Holdings, Inc. (RANI) most recently reported earnings on May 15, 2026 for Q2 FY2026, posting EPS of $-0.04 — beating the analyst consensus of $-0.06 by +33.3%. The next RANI earnings date is expected around September 1, 2026.
Each quarter, investors track RANI earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. RANI revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
RANI's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
RANI earnings · 5 questionsRani Therapeutics Holdings, Inc.'s next earnings report is expected around September 1, 2026. RANI typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; RANI historically reports after market close (AMC).
RANI earnings datewhen is RANI earningsRANI next earnings datewhen does RANI report earningsRANI earnings calendar
▸ Source: FMP · Rani Therapeutics Holdings, Inc. SEC filings · US GAAP · Rani Therapeutics Holdings, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026